152 related articles for article (PubMed ID: 12240944)
21. Subchronic oral toxicity of salcaprozate sodium (SNAC) in Sprague-Dawley and Wistar rats.
Riley MG; Castelli MC; Paehler EA
Int J Toxicol; 2009; 28(4):278-93. PubMed ID: 19636071
[TBL] [Abstract][Full Text] [Related]
22. Phase I clinical study to select a novel oral formulation for ibandronate containing the excipient sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC).
Bittner B; McIntyre C; Tian H; Tang K; Shah N; Phuapradit W; Ahmed H; Chokshi H; Infeld M; Fotaki N; Ma H; Portron A; Jordan P; Schmidt J
Pharmazie; 2012 Mar; 67(3):233-41. PubMed ID: 22530305
[TBL] [Abstract][Full Text] [Related]
23. Gastrointestinal absorption of heparin by lipidization or coadministration with penetration enhancers.
Ross BP; Toth I
Curr Drug Deliv; 2005 Jul; 2(3):277-87. PubMed ID: 16305430
[TBL] [Abstract][Full Text] [Related]
24. Oral heparin: status review.
Arbit E; Goldberg M; Gomez-Orellana I; Majuru S
Thromb J; 2006 May; 4():6. PubMed ID: 16686945
[TBL] [Abstract][Full Text] [Related]
25. Synthesis of salcaprozate sodium and its significance in enhancing pancreatic kininogenase absorption performance.
Lv Z; Luo QD; Tang ZY; Lv XH; Wu T; Huang LK; Tang C
Pharmacol Res Perspect; 2024 Apr; 12(2):e1186. PubMed ID: 38511246
[TBL] [Abstract][Full Text] [Related]
26. Hydroxy-safflower yellow A composites: An effective strategy to enhance anti-myocardial ischemia by improving intestinal permeability.
Bao D; Xie X; Cheng M; Zhang K; Yue T; Liu A; Fang W; Wei Y; Zheng H; Piao JG; Xu D; Li Y
Int J Pharm; 2022 Jul; 623():121918. PubMed ID: 35716973
[TBL] [Abstract][Full Text] [Related]
27. Current Understanding of Sodium N-(8-[2-Hydroxylbenzoyl] Amino) Caprylate (SNAC) as an Absorption Enhancer: The Oral Semaglutide Experience.
Solis-Herrera C; Kane MP; Triplitt C
Clin Diabetes; 2024; 42(1):74-86. PubMed ID: 38230324
[TBL] [Abstract][Full Text] [Related]
28. Physical and barrier changes in gastrointestinal mucus induced by the permeation enhancer sodium 8-[(2-hydroxybenzoyl)amino]octanoate (SNAC).
Mortensen JS; Bohr SS; Harloff-Helleberg S; Hatzakis NS; Saaby L; Nielsen HM
J Control Release; 2022 Dec; 352():163-178. PubMed ID: 36314534
[TBL] [Abstract][Full Text] [Related]
29. Modulation of intestinal barrier properties by miltefosine.
Menez C; Buyse M; Chacun H; Farinotti R; Barratt G
Biochem Pharmacol; 2006 Feb; 71(4):486-96. PubMed ID: 16337152
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics and pharmacodynamics of oral heparin solid dosage form in healthy human subjects.
Mousa SA; Zhang F; Aljada A; Chaturvedi S; Takieddin M; Zhang H; Chi L; Castelli MC; Friedman K; Goldberg MM; Linhardt RJ
J Clin Pharmacol; 2007 Dec; 47(12):1508-20. PubMed ID: 18048572
[TBL] [Abstract][Full Text] [Related]
31. Roles of ZO-1, occludin, and actin in oxidant-induced barrier disruption.
Musch MW; Walsh-Reitz MM; Chang EB
Am J Physiol Gastrointest Liver Physiol; 2006 Feb; 290(2):G222-31. PubMed ID: 16239402
[TBL] [Abstract][Full Text] [Related]
32. SNAC for Enhanced Oral Bioavailability: An Updated Review.
Kommineni N; Sainaga Jyothi VGS; Butreddy A; Raju S; Shapira T; Khan W; Angsantikul P; Domb AJ
Pharm Res; 2023 Mar; 40(3):633-650. PubMed ID: 36539668
[TBL] [Abstract][Full Text] [Related]
33. Correlation between oral drug absorption in humans, and apparent drug permeability in TC-7 cells, a human epithelial intestinal cell line: comparison with the parental Caco-2 cell line.
Grès MC; Julian B; Bourrié M; Meunier V; Roques C; Berger M; Boulenc X; Berger Y; Fabre G
Pharm Res; 1998 May; 15(5):726-33. PubMed ID: 9619781
[TBL] [Abstract][Full Text] [Related]
34. Influence of Bile Composition on Membrane Incorporation of Transient Permeability Enhancers.
Hossain S; Joyce P; Parrow A; Jõemetsa S; Höök F; Larsson P; Bergström CAS
Mol Pharm; 2020 Nov; 17(11):4226-4240. PubMed ID: 32960068
[TBL] [Abstract][Full Text] [Related]
35. Monoketocholate can decrease transcellular permeation of methotrexate across Caco-2 cell monolayers and reduce its intestinal absorption in rat.
Chen G; Fawcett JP; Mikov M; Tucker IG
J Pharm Pharmacol; 2009 Jul; 61(7):953-9. PubMed ID: 19589239
[TBL] [Abstract][Full Text] [Related]
36. Enhancement by adrenaline of ginsenoside Rg1 transport in Caco-2 cells and oral absorption in rats.
Xiong J; Sun M; Guo J; Huang L; Wang S; Meng B; Ping Q
J Pharm Pharmacol; 2009 Mar; 61(3):347-52. PubMed ID: 19222907
[TBL] [Abstract][Full Text] [Related]
37. Permeability enhancement in Caco-2 cell monolayers by sodium salicylate and sodium taurodihydrofusidate: assessment of effect-reversibility and imaging of transepithelial transport routes by confocal laser scanning microscopy.
Hurni MA; Noach AB; Blom-Roosemalen MC; de Boer AG; Nagelkerke JF; Breimer DD
J Pharmacol Exp Ther; 1993 Nov; 267(2):942-50. PubMed ID: 7504101
[TBL] [Abstract][Full Text] [Related]
38. Peri- and postnatal developmental toxicity of salcaprozate sodium (SNAC) in Sprague-Dawley rats.
Riley MG; York RG
Int J Toxicol; 2009; 28(4):266-77. PubMed ID: 19636070
[TBL] [Abstract][Full Text] [Related]
39. Docosahexaenoic acid and eicosapentaenoic acid-enriched phosphatidylcholine liposomes enhance the permeability, transportation and uptake of phospholipids in Caco-2 cells.
Hossain Z; Kurihara H; Hosokawa M; Takahashi K
Mol Cell Biochem; 2006 Apr; 285(1-2):155-63. PubMed ID: 16477371
[TBL] [Abstract][Full Text] [Related]
40. Uptake and transport of PEG-graft-trimethyl-chitosan copolymer-insulin nanocomplexes by epithelial cells.
Mao S; Germershaus O; Fischer D; Linn T; Schnepf R; Kissel T
Pharm Res; 2005 Dec; 22(12):2058-68. PubMed ID: 16170693
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
